Taxane-anthracycline combination improves survival of patients with early breast cancer.

The article discusses research on the effectiveness of supplementing an anthracycline-based therapy with taxane in increasing the survival rate of high-risk early breast cancer patients. It references a study published in a 2008 issue of the "Journal of Clinical Oncology." Researchers have examined hazard ratios and confidence intervals for disease-free survival and overall survival from trials. The study revealed that taxane administration could have an absolute five-year risk reduction of 3% overall survival and 5% for disease-free survival.